Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”-Reference-Cited by-同舟云学术

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

Published:2013-06-03 Issue:1 Volume:11 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Ascierto Paolo A,Grimaldi Antonio M,Acquavella Nicolas,Borgognoni Lorenzo,Calabrò Luana,Cascinelli Natale,Cesano Alessandra,Del Vecchio Michele,Eggermont Alexander M,Faries Mark,Ferrone Soldano,Fox Bernard A,Gajewski Thomas F,Galon Jérôme,Gnjatic Sacha,Gogas Helen,Kashani-Sabet Mohammed,Kaufman Howard L,Larkin James,Lo Roger S,Mantovani Alberto,Margolin Kim,Melief Cornelis,McArthur Grant,Palmieri Giuseppe,Puzanov Igor,Ribas Antoni,Seliger Barbara,Sosman Jeff,Suenaert Peter,Tarhini Ahmad A,Trinchieri Giorgio,Vidal-Vanaclocha Fernando,Wang Ena,Ciliberto Gennaro,Mozzillo Nicola,Marincola Francesco M,Thurin Magdalena

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1479-5876-11-137.pdf

Reference116 articles.

1. Clark WH, From L, Bernardino EA, Mihm MC: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969, 29: 705-727.

2. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008, 26: 527-534. 10.1200/JCO.2007.12.7837.

3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010, 363: 809-819. 10.1056/NEJMoa1002011.

4. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012, 379: 1893-1901. 10.1016/S0140-6736(12)60398-5.

5. Van den Eynde BJ, van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol. 1997, 9: 684-693. 10.1016/S0952-7915(97)80050-7.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Improved Anticancer Efficacies of Camptothecin Nano-Formulations: A Systematic Review;Biomedicines;2021-04-27

2. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation;Journal of Translational Medicine;2021-01-06

3. Genetics, molecular biomarkers, and artificial intelligence to improve diagnostic and prognostic efficacy;Principles of Translational Science in Medicine;2021

4. Role of interferon in melanoma: old hopes and new perspectives;Expert Opinion on Biological Therapy;2017-02-16

5. Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma;Biologics: Targets and Therapy;2016-07